Research
-
Impact of the COVID-19 Pandemic on the Kidney Community: Lessons Learned and Future Directions
Researchers investigate the impact of COVID-19 on kidney care.
Categorized in -
The Cannabis Policy Scale: A New Research and Surveillance Tool for U.S. States
USC researchers developed composite measures to characterize the restrictiveness of U.S. state cannabis policy environments.
Categorized in -
Association of Fatal Overdose Notification Letters With Prescription of Benzodiazepines
New research builds on a landmark USC Schaeffer Center study aimed at reducing opioid overprescribing.
Categorized in -
Development and Pilot Testing of EHR-Nudges to Reduce Overuse in Older Primary Care Patients
Unnecessary testing and treatment of common conditions in older adults can lead to significant morbidity and mortality.
Categorized in -
Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
How have out-of-pocket (OOP) costs for naloxone in the US changed between 2010 and 2018 overall and by drug brand and payer?
-
Characterization of Cannabis Products Purchased for Medical Use in New York State
Schaeffer Center researchers analyzed point-of-sale data from nearly 17,000 medical cannabis patients making 80,000 purchases.
Categorized in -
Price Changes Varied Widely Across California Hospital Systems from 2012 through 2018
Researchers compared prices changes within system and nonsystem hospitals in California.
Categorized in -
Association of Direct-to-Consumer Advertising of Prescription Drugs With Consumer Health-Related Intentions and Beliefs Among Individuals at Risk of Cardiovascular Disease
Consumers in the US are exposed to unprecedented high levels of direct-to-consumer advertising (DTCA) for prescription drugs, yet there is limited evidence regarding their effect on health-related intentions and beliefs.
Categorized in -
Spatial and Temporal Trends in the Diagnosis of Opioid-Related Problems in Commercially-Insured Adolescents and Young Adults
USC researchers looked at claims data from privately insured individuals with an opioid-related problem.
Categorized in -
Recommendations To Address Key Recruitment Challenges of Alzheimer’s Disease Clinical Trials
An advisory panel of experts convened in 2020 to assess the critical challenges facing recruitment in Alzheimer’s clinical trials and develop a set of recommendations to overcome them.